Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

March 6, 2018
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update

February 28, 2018
Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases

February 27, 2018
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results

Read More News

Associated Team Members

Alexis Borisy